You searched for "presentation"
Barriers to use of semen analysis in the adolescent with a varicocele
This paper tries to address the question of identifying the cause of the difficulty in obtaining a semen analysis (SA) in adolescents with a varicocele in order to try to find improved strategies in giving patient advice, treatment and care....Nonacus Clinical Services announce partnership with The London Clinic to deliver GALEAS™ Bladder test
Nonacus Clinical Services, the UK laboratory delivering genomic cancer testing services to the NHS and private healthcare providers, recently announced it is working with The London Clinic to help more patients benefit from its non-invasive GALEAS™ Bladder test for cancer....Making the most of BJUI Knowledge – a trainee’s perspective
BJUI Knowledge combines online continuing professional development (CPD) content for urologists with a platform for recording all CPD activity in one place. This also makes it a useful resource for urological trainees. This article will outline how to use BJUI...A report from the second laparoscopic urology workshop in Dakar, Senegal
Hôpital Général Idrissa Pouye (HOGIP), formerly Hôpital Général de Grand Yoff – HOGGY), in Dakar, Senegal, is one of the most well-regarded teaching hospitals in West Africa. It has over 300 beds, a urology team of six consultants and attracts...Recent developments in bladder cancer – NMIBC
Every year, roughly 10,300 individuals are diagnosed with bladder cancer in the UK, making it the 11th most common cancer in the UK, and the eighth most common cancer in men [1]. Of those diagnosed with the disease, 75-85% will...Renal oncocytoma: Diagnosis and surveillance strategy
Renal oncocytoma is one of the most common benign renal neoplasms, accounting for around 3–7% of all renal tumours, and up to 18% of all small renal masses (SRMs) measuring less than 4cm [1, 2]. Most oncocytomas are asymptomatic and...Biomarkers in prostate cancer detection
Prostate cancer (PCa) is the second most common cancer in men with an estimated prevalence of 1.1 million worldwide in 2012. This heterogeneous disease resulted in approximately 307,000 deaths, making it the fifth leading cause of cancer-related death in men...
Morbidity and mortality after surgery for LUTS
The market for bladder outflow obstruction surgery is currently wide open with new technologies such as Urolift® emerging. One of the key selling points of new technologies is the comparative safety and efficacy compared to traditional techniques such as transurethral...
ABU joins BCG in fight against NMIBC recurrence?
The authors test a hypothesis retrospectively in two cohorts of patients with non-muscle invasive bladder cancer (NMIBC), that endogenous bacteria in the bladder might exert antitumour effects, similar to live mycobacteria (BCG), through local immune-related or other mechanisms, on NMIBC...
Active surveillance for renal neoplasms
Renal oncocytomas are the second most common benign renal tumours and they originate from the collecting tubules. They appear genotypically very similar to chromophobe renal cell carcinomas (chRCC), which also contain eosinophilic cells. Oncocytomas are often found incidentally on routine...
RCC recurrence rates post laparascopic partial nephrectomy
In recent years laparascopic partial nephrectomy (LPN) has emerged as an oncologically safe alternative to its radical nephrectomy counterpart. There is however a lack of consensus amongst the urology community regarding surveillance after LPN for patients with stage I tumours....
